4Branchi A, Bovellini R, Sommariwa D, et al. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors in patients with primary hypercholesterolemia [J]. Thromb Heamost, 1993,70 .- 241-243.
5Nilsson L, Takemura T, Eriksson P, et al. Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells [J]. Arterioscler Thromb Vasc Biol,1999,19:1577-1581.
6Ross R. Atherosclerosis an inflammatory disease[J]. N Engl J Med. 1999,340:115-126.
7Shah PK. Plaque disruption and thrombosis: potential role of inflammation and infection[J]. Cardiol Clin, 1999,17:270-281.
8Schumacher A, Seljeflot I, Sommervoll L, et al. Increased levels of markers of vascular inflammation in patients with coronary heart disease[J]. Scand J Clin Lab Invest, 2002,62 : 59- 68.
9Valen G, Yan ZQ, hansson Gk. Nuclear factor kappa-B and the heart[J]. J Am Coll Cardiol, 2001,38:307-314.
10Wilson SH, Best PJ, Edwards WS, et al. Nuclear factor kappa-B immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectors[J]. Atherosclerosis, 2002,161 : 147-153.
